Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:erlotinib
|
| gptkbp:administeredBy |
oral
|
| gptkbp:affiliatedWith |
tyrosine kinase inhibitors
quinazoline derivatives |
| gptkbp:approvedBy |
gptkb:FDA
2004 |
| gptkbp:ATCCode |
L01EB02
|
| gptkbp:CASNumber |
183321-74-6
|
| gptkbp:chemicalFormula |
C22H23N3O4
|
| gptkbp:developedBy |
gptkb:Genentech
gptkb:OSI_Pharmaceuticals |
| https://www.w3.org/2000/01/rdf-schema#label |
Taceva
|
| gptkbp:indication |
locally advanced, unresectable or metastatic pancreatic cancer
locally advanced or metastatic non-small cell lung cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
EGFR inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea anorexia fatigue rash |
| gptkbp:synonym |
erlotinib hydrochloride
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
pancreatic cancer |
| gptkbp:bfsParent |
gptkb:Taceva,_Romania
|
| gptkbp:bfsLayer |
7
|